Their medical-speak was out of my ballpark, but I think I got the gist.

Was the purpose related to..

(1) Allergic reactions abatement


(2) Drug overdose/alc. poisoning

(3) Dosing control ("The application of therapeutic drug monitoring to
avoid the risk of treatment failure is highly recommended.") That's my guess.


-other?


I'm curious what diseases/indications would call for:

ceftazidime, ciprofloxacin), flucloxacillin, fluconazole, gentamicin, linezolid, meropenem, metronidazole, piperacillin, vancomycin and voriconazole (10 mg/l)


Are they all related to ESRD? There are other diseases besides ESRD for this experiment/ filtration test.
Are any of them be in clinical-safety trials?

("In the meantime it appears advisable to use maximum approved dosages e.g. meropenem 6g/24h, piperacilline 16g/24h or
ceftazidime 9g/24h in patients without renal failure.)


***********************************
Anybody understand the what & why of this? Ascertain point of overdosing?

"Further studies are needed to investigate the performance of the filter in the presence of blood
components regarding adsorption and possible saturation effects at the binding sites as well as to
quantify these effects to substantiate adequate dosing recommendations.

I don't know. You know?

IS THERE A DOCTOR IN THE HOUSE!?

In the first 3 lines, gotta like those words "other" and "investigations" (plural)

ThesT,
Thank you for your reply.

"..company would be able to access a known and previously disqualified pool of patients (i.e. they already know the numbers)?"

Bingo.

Furthermore, what other, AEMD-relevant diseases might this same/similar situation apply to?

Hmmm.

Food for thought and a lil' research.

Yoohoo! ThesT!

...5..4..3..2..1....

Google - 2014 Medicare HCV policy changes
*****************************
May 16, 2014

"Medicare Eases Restrictions On Pricey Hepatitis C Treatment"

"..3 million to 5 million Americans are infected with hepatitis C....



"Sovaldi plus Olysio. Together they cost about $150,000" ( 'O' !!!!)

"Medicare coverage of the new drugs, alone or in combination, is expected to have enormous cost implications"

Now, that'$ motivation to u$e the HP.

Ya think?

Perhaps, with higher volume, but lower doses, Gilead still wins. (?)

http://www.npr.org/blogs/health/2014/05/16/313025946/medicare-eases-restrictions-on-pricey-hepatitis-c-treatment

Please, would some of yous guys leave an educational comment here:

http://www.npr.org/blogs/health/2014/05/16/313025946/medicare-eases-restrictions-on-pricey-hepatitis-c-treatment?ft=1&f=1001

How much will 1 HP filtration cost in US $? Anybody know?

Are Medicare, and the Fed'&$tate exchange$ aware?

From earlier post (of Zacks report, post #5297), "Patient registry where case studies and clinical outcomes data will be kept - THIS IS EXPECTED TO GO LIVE IN JUNE OF THIS YEAR."

Q: Will this be a publically available site?

Q: Zacks, chart near bottom, has the OS rising from 301.9K (2014) to 610K (2017). You agree?

April 23, 2014 FDA proposes accelerated medical device approval plan
http://medicalxpress.com/news/2014-04-fda-medical-device.html

Q: Is there any way to monitor the progress of this?

ThesT, gotta question.....

I had some conversations w/ some med'friends about your "interesting conversation w/ an MD."

"..viral load...determines treatment and payment."(your post #5161)

Was your MD friend (or you) implying that, to be a successful/optimal adjunctive therapy, the HP should be used first, before any pharmo is introduced - in order to maintain insurer reinbursement, and/or to enable effective and safe treatment of someone w/ compromised renal health?

Thusly, it seems the HP could lower the costs to the insurer, the health care provider and the patient (while saving more lives?).

Those are interesting parameters you brought up.
Did I understand it correctly?

Thank you.

BTW, might your MD friend consider possible the coordinated/simultaneous use of the HP (antipathogenic) with the cytosorb(antiseptic), in certain dire situations?

WHY NOT CTSO?

"Right-To-Try"

Colorado, other states will follow.

This is a device, not a drug (phases 1,2,3)

http://www.dddmag.com/news/2014/05/colo-governor-signs-controversial-right-try-bill

Well? Why not?

Likewise posted on AEMD board.

People are dying unnecessarily.

WHY NOT AEMD?

Right-To-Try

Colorado, other states will follow.

This is a device, not a drug (phases 1,2,3)

http://www.dddmag.com/news/2014/05/colo-governor-signs-controversial-right-try-bill

Well? Why not?

AEMD's first customer?

DaVita centers, over 2000 ( that would be alot of filters sold)
Browse by state.
http://www.davita.com/find-a-dialysis-center/

"Among dialysis patients, where the prevalence of HCV infection is relatively high.."

"DaVita Labs will also evaluate viral load testing for Hepatitis B, HIV and cytomegalovirus – all of which are FDA-approved tests – on the Roche
quantitative PCR platform."
http://phx.corporate-ir.net/phoenix.zhtml?c=76556&p=irol-newsArticle&ID=1927990&highlight=

"Additionally, their proximity to M.D. Anderson Cancer Center and other specialty facilities located within the Texas Medical Center provide for a unique location to conduct future clinical investigations of Hemopurifier(R) therapy in a variety of life-threatening health conditions," stated Aethlon Medical CEO Jim Joyce.

"DaVita Kidney Care strives to improve patients' quality of life by innovating clinical care....
2,098 outpatient dialysis centers located in the United States serving approximately 165,000 patients. The company also operated 75 outpatient dialysis centers located in 10 countries outside the United States.
http://online.wsj.com/article/PR-CO-20140520-906474.html

Multiple Myeloma cured.

http://www.kare11.com/story/news/health/2014/05/14/mayo-clinic-trial-measles-vaccine-multiple-myeloma/9101893/

Biocon?
I think they had a recent ER.
Did they mention sales trend/#s.
If not, ant way to ascertain that?

Make some headlines?

Try the HP on:


Middle East Respiratory Syndrome (MERS)

Clostridium difficile (C. Diff)

Methicillin-resistant Staphylococcus aureus ( MRSA)

Necrotizing fasciitis (NF)

Polio (now renascent in Pakistan)

FDA proposes new expedited access program for medical devices.This may be very important for CTSO. Google FDA news. FDA proposes new expedited access program for medical devices that address unmet medical needs. To be eligible for participation in the program, the medical device must:
• Be intended to treat or diagnose a life-threatening or irreversibly-debilitating disease or condition
• Represent one of the following:
1. no approved alternative treatment/diagnostic exists, or
2. a breakthrough technology that provides a clinically meaningful advantage over existing technology, or
3. offers a significant, clinically meaningful advantage over existing approved alternatives, or
4. availability is in the patient’s best interest
• Have an acceptable data development plan that has been approved by the FDA

Re post # 193

EU Crisis Summit Poised For Energy Policy Changes
".. the Brussels talks will debate the European Union’s “indigenous supplies”, which include renewable energy and shale gas."—Barbara Lewis, Reuters, 19 March 2014
" But the message is clear: in a time of austerity, and with international energy security disturbed, the priority is cheap abundant energy, not cutting down on energy use to limit CO2 emissions. That is simply a recognition of political reality."—Andrew Lilico, City A.M., 20 March 2014
http://canadafreepress.com/index.php/article/61882
EU Leaders Delay Decision On Climate Targets
"A debate that was meant to set the stage for agreement on a new target instead became focused on reducing Europe’s energy dependence on Russia."—Dave Keating, European Voice, 21 March 2014
"concerned that the targets will increase dependence on Russian energy because it would make it difficult for them to use what little domestic energy sources they have – mainly coal and shale gas."—Dave Keating, European Voice, 21 March 2014
" UK Onshore Gas, which will start drilling in June, believes that Wales is sitting on so much shale gas that it will start exporting it to the rest of the world.—Tim Webb, The Times, 21 March 2014
http://canadafreepress.com/index.php/article/61919

Methusila

Thanks for your layman's terms answer.
My other question, which I have not seen adequately addressed due perhaps to the nascent stage of this sector:

Given AEMD's patents, do they own certain target markets, as there are others in the exosome space*?


*QGEN, CarisLife, CTSO, LIFE(now acquired), Reneuron, Exo' Diagnostics

OPPORTUNITY(IES)?

Breaking news:

"Now European leaders are admitting quietly that they want to get into the game of fracking and other new drilling technologies that have caused an explosion of oil and gas production in the U.S.

"
European leaders agreed to scrap per-nation caps on carbon emissions...
Now those caps won't apply to individual nations.

"in recent weeks Europe has decided to run, not walk, as fast as it can away from the economic menace of green energy. Brussels calls this new policy “flexibility.” Right. More like “never mind,” and here’s why: The new German economic minister, Sigmar Gabriel, says green energy mandates have become such an albatross around the neck of industry that they could lead to a “deindustrialization” of Germany."

"According to energy expert Daniel Yergin, if Europe wants to remain competitive, these nations must tap the fountain of abundant and cheap shale gas and oil. He recently wrote that European leaders now realize a major factor behind the economic woes in euroland is that electric power costs are "two to three times more expensive" than in the U.S.

http://news.investors.com/ibd-editorials/020514-689033-europe-finds-anti-co2-policies-are-destroying-the-economy.htm

Help here?

If I understand this right...
How do they identify and act on (block uptake) of tissue(tumor)-specific exosomes?

Or, on the other hand, allow for proper uptake of those exosomes that would prevent auto-immune disease of, say, the pancreas?

Can the HP differentiate between exosomes yet? How?

http://www.nzherald.co.nz/health/news/article.cfm?c_id=204&objectid=11197101

"One of Apple's inventions published today relates to methods of constructing a part using bulk metallic glasses (BMG - Liquidmetal) layer by layer. In one embodiment, a layer of BMG powder is deposited to selected positions and then fused to a layer below by suitable methods such as laser heating or electron beam heating. The deposition and fusing are then repeated as need to construct the part layer by layer. One or more layers of non-BMG can be used as needed. In one embodiment, layers of BMG can be cut from one or more sheets of BMG to desired shapes, stacked and fused to form the part. Apple's primary example of this invention focuses in on 3D printing."
http://www.patentlyapple.com/patently-apple/2013/11/apple-seeks-patents-for-five-new-liquidmetal-inventions-covering-3d-printing-and-more.html

Say, the Apple printer doesn't require LM alloy as a component,

Would the user order their print catridges ("BMG sheet feedstock") from Apple, LQMT, other?
who gets paid?

Re the article/Apple agreement

Question

Does it or not allow, based on production/sales, for royalty payments from Apple?

TRUTHTELLER,

A stand up grandslam - If CTSO's filter could prevent/reduce the often deadly brainswelling due to brain injury. Just hook'er up to the carotid?

What markets/applications could they share w/ AEMD? And, not share? Patent differences?

I ask the same about this one:

QGEN

"•Expanding collaboration to develop FDA-regulated diagnostics based on exosomes to measure gene mutations targeted by new anti-cancer therapies
•Non-invasive detection of biomarkers from blood reduces patient risk and advances access to the benefits of personalized medicine
•Automated biofluid-based molecular diagnostics have significant potential to replace many costly and invasive tissue biopsies and add new testing options
•QIAGEN set to launch during 2014 the first in a series of new sample preparation kits for processing nucleic acids from biofluid exosomes"

http://finance.yahoo.com/news/qiagen-exosome-diagnostics-develop-first-070000686.html